araag2/HINT huggingface dataset:
Clinical trial NCT01096667 (phase 2, status: completed)
Conditions: diabetes mellitus, type 2, hypertension
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44, I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10
Drugs: placebo to ertuglilflozin 1 or 5 mg, ertugliflozin 1 mg, ertugliflozin 5 mg, ertugliflozin 25 mg, hctz 12.5mg, placebo to hctz, placebo to ertuglilflozin 25 mg
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CCOC1=CC=C(CC2=CC(=CC=C2Cl)[C@]23OC[C@](CO)(O2)[C@@H](O)[C@H](O)[C@H]3O)C=C1, CCOC1=CC=C(CC2=CC(=CC=C2Cl)[C@]23OC[C@](CO)(O2)[C@@H](O)[C@H](O)[C@H]3O)C=C1, CCOC1=CC=C(CC2=CC(=CC=C2Cl)[C@]23OC[C@](CO)(O2)[C@@H](O)[C@H](O)[C@H]3O)C=C1, NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1, NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Participants with type 2 diabetes and hypertension

          -  Medically stable

          -  On at least 1 (and up to 2) oral diabetes drugs

          -  And up to 2 medicines for blood pressure control

        Exclusion Criteria:

          -  Participants with type 1 diabetes

          -  Heart attack

          -  Stroke

          -  Uncontrolled blood pressure

          -  Significant kidney disease
Clinical trial NCT00594256 (phase 2, status: completed)
Conditions: schizophrenia, insomnia related to schizophrenia (307.42)
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9, F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: sodium oxybate
SMILES: [Na+].OCCCC([O-])=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients aged 18-45 with a DSM-IV diagnosis of schizophrenia and insomnia related to
             schizophrenia, confirmed by a structured interview (SCID).

        Exclusion Criteria:

          -  Lack of capacity to give informed consent (capacity is determined by a licensed member
             of the treatment team).

          -  Unstable medical illness.

          -  Diagnosis of restless leg syndrome, a seizure disorder, uncontrolled hypertension,
             unstable cardiac illness, or obstructive sleep apnea.

          -  Pregnancy or lack of adequate birth control.

          -  History of substance dependence disorder.

          -  Current treatment with valproic acid.

          -  Succinic semialdehyde dehydrogenase deficiency (SSADH).

          -  Persistent need for treatment with benzodiazepines, barbiturates, opiates or other
             sedative hypnotics.
Clinical trial NCT00528411 (phase 2, status: completed)
Conditions: coronary artery disease
ICD codes: I25.10, I25.110, I25.119, I25.111, I25.118
Drugs: ticagrelor tablets, clopidogrel (over encapsulated) capsule, aspirin tablets
SMILES: CCCSC1=NC2=C(N=NN2[C@@H]2C[C@H](OCCO)[C@@H](O)[C@H]2O)C(N[C@@H]2C[C@H]2C2=CC(F)=C(F)C=C2)=N1, [H][C@@](N1CCC2=C(C1)C=CS2)(C(=O)OC)C1=CC=CC=C1Cl, CC(=O)OC1=CC=CC=C1C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Documented stable Coronary Artery Disease (stable angina, previous MI history,
             previous history of revascularization);

          -  Females of child bearing potential must have a negative pregnancy test prior to
             receiving study drug and be willing to use a hormonal contraceptive in addition to
             double barrier contraception

        Exclusion Criteria:

          -  History of Acute Coronary Syndromes within 12 months of screening or need for
             revascularization (angioplasty or Coronary Artery Bypass Graft (CABG))

          -  History of liver or kidney disease

          -  Have increased bleeding risk, eg, recent gastrointestinal bleed, uncontrolled high
             blood pressure, low platelet count, recent major trauma

          -  History of intolerance or allergy to Aspirin or clopidogrel
Clinical trial NCT01200602 (phase 2, status: terminated)
Conditions: anorexia, weight changes
ICD codes: R63.0, F50.00, F50.01, F50.02
Drugs: megestrol acetate
SMILES: [H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C=C(C)C2=CC(=O)CC[C@]12C
Reason stopped: 
    the study closed due to slow accrual.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Any pediatric patient with an underlying diagnosis of a malignancy (excluding
             hematological malignancies like leukemias and lymphomas)

          -  ≥5% weight loss from diagnosis of primary malignancy (must be currently on
             chemotherapy and/or radiation therapy or scheduled to receive cancer therapy OR ≥5%
             weight loss following bone marrow transplant (autologous or allogeneic blood/bone
             marrow) and not actively receiving corticosteroid therapy

          -  Negative pregnancy test done =< 7 days prior to registration for women of childbearing
             potential only

        Exclusion Criteria:

          -  Receiving tube feedings or parenteral nutrition

          -  Evidence of ascites

          -  Current (within the past 28 days) or planned treatment with adrenal steroids
             (short-term use of dexamethasone around days of intravenous chemotherapy is allowed
             for protection against emesis), androgens, progestational agents, or appetite
             stimulants (e.g., dronabinol)

          -  Known mechanical obstruction of the alimentary tract, malabsorption, or intractable
             vomiting (> 5 episodes/week)

          -  History of unresectable brain tumor or cancer metastatic to the brain

          -  History of thromboembolic disease

          -  Insulin-requiring diabetes

          -  Congestive heart failure and/or uncontrolled hypertension

          -  Anticoagulation

          -  Previous history of thrombosis (personal and immediate family)

          -  Concurrent corticosteroid therapy (except as an antiemetic)
Clinical trial NCT01229332 (phase 1/phase 2, status: completed)
Conditions: parkinson's disease
ICD codes: G20
Drugs: saline, carbidopa
SMILES: COCCC1=CC=C(OCC(O)CNC(C)C)C=C1, C[C@@](CC1=CC(O)=C(O)C=C1)(NN)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          1. Men and women with idiopathic Parkinson's disease

          2. Subjects must experience motor fluctuations associated with LD/CD dosing

          3. Modified Hoehn and Yahr stage < 5

          4. Subjects must be taking optimized and stable levodopa/dopa decarboxylase inhibitor
             therapy

          5. Women must be postmenopausal, surgically sterilized, or using adequate birth control.
             Women of childbearing potential must have a negative pregnancy test (serum beta-HCG)
             at screening.

          6. Subjects must be age 30 or older.

          7. Subjects must be willing and able to give informed consent.

        Exclusion Criteria:

          1. Subjects with a clinically significant or unstable medical or surgical condition

          2. Subjects with clinically significant psychiatric illness.

          3. Pre-menopausal women, not using birth control method.

          4. Subjects who have taken experimental medications within 60 days prior to baseline.

          5. Subject who have undergone a neurosurgical intervention for Parkinson's disease (e.g.,
             pallidotomy, thalamotomy, transplantation and deep brain stimulation).
Clinical trial NCT00623363 (phase 2, status: completed)
Conditions: parkinson's disease
ICD codes: G20
Drugs: piclozotan, 0.9% sodium chloride (normal saline)
SMILES: ClC1=COC2=CC=CC=C2C(=O)N1CCCCN1CCC(=CC1)C1=CC=CC=N1, [Na+].[Cl-]
Eligibility criteria:

        Main Inclusion Criteria:

          -  Idiopathic Parkinson's disease for at least 5 years

          -  Presence of motor fluctuations and dyskinesia

          -  Stable regimen of levodopa/carbidopa for 30 days

          -  At least 25% response/improvement in UPDRS part III scores after dosing with regular
             PD medications

          -  MMSE score of 25 or higher

        Main Exclusion Criteria:

          -  Atypical or secondary parkinsonism.

          -  Prior use of neuroleptic agents.

          -  History of intracranial procedures for PD.

          -  Active psychosis.

          -  History of drug or alcohol abuse in past 12 months.

          -  Cardiac conduction system abnormality.

          -  Predisposing medical condition that causes nausea or vomiting or routine use of an
             anti-emetic.
Clinical trial NCT00074165 (phase 2, status: terminated)
Conditions: brain and central nervous system tumors, drug/agent toxicity by tissue/organ, lymphoma, thrombocytopenia
ICD codes: T86.91, T86.92, T86.93, Z52.9, Z94.89, Z94.9, T86.90, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, D69.6, D69.49, D69.59, P61.0, D75.82, D69.42, O36.8211
Drugs: rituxan, cyclophosphamide, etoposide, etoposide phosphate, carboplatin, sodium thiosulfate, neupogen, neulasta, cytarabine
SMILES: [H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C, ClCCN(CCCl)P1(=O)NCCCO1, OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1, CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(C=CC(O)=C4CN(C)C)N=C13)C2=O, N[C@@H](CCCNC(N)=N)C(O)=O, OS(O)(=O)=S, C(N1CCCNCCNCCCNCC1)C1=CC=C(CN2CCCNCCNCCCNCC2)C=C1, ClCCN(CCCl)P1(=O)NCCCO1
Reason stopped: 
    lack of accrual
  
Eligibility criteria:

        INCLUSION CRITERIA:

          -  Signed informed consent form in accordance with institutional guidelines

          -  Histologically or cytologically confirmed primary CNS lymphoma documented by brain
             biopsy or cerebrospinal fluid or vitrectomy analysis

          -  CD20 positive disease

          -  Progressive or relapsed disease during or after completion of prior methotrexate-based
             chemotherapy

          -  Aged 18 months to 75 years

          -  Performance status ECOG 0-3 OR Karnofsky 30-100%

          -  Hematocrit at least 25% (transfusion or epoetin alfa allowed)

          -  Absolute granulocyte count at least 1,200/mm^3

          -  Platelet count at least 100,000/mm^3 OR at least lower limit of normal

          -  Bilirubin no greater than 2.0 times upper limit of normal

          -  Creatinine less than 1.8 mg/dL

          -  Calculated Creatinine clearance (CrCl) at least 50 mL/min

          -  Adequate cardiac function to tolerate general anesthesia

          -  Adequate pulmonary function to tolerate general anesthesia

          -  Available for follow-up for 1 year post therapy

          -  Fertile patients must use effective contraception for a minimum of 2 months before and
             during study participation

        EXCLUSION CRITERIA:

          -  Radiographic signs of intra-cranial herniation and/or spinal block

          -  HIV positive

          -  Systemic lymphoma

          -  Positive serum HCG, pregnant or lactating

          -  Allergy to study agents

          -  Hepatitis B or hepatitis C positive
Clinical trial NCT01597050 (phase 2, status: completed)
Conditions: lupus erythematosus, discoid, lupus erythematosus, systemic
ICD codes: M32.9, M32.0, M32.11, M32.12, M32.13, M32.14, M32.8
Drugs: r932333, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of SLE or DLE (DLE confirmed histologically prior to randomization).

          -  At least 2 active discoid lesions secondary to SLE or DLE prior to study entry, each
             with a minimum Erythema Rating Score of ≥ 2. At least 1 of the active discoid lesions
             must have been present (by history) for ≥ 3 weeks prior to screening.

          -  Patients who are taking azathioprine, hydroxychloroquine, chloroquine, quinacrine,
             methotrexate, and/ or oral glucocorticoids, must be receiving a stable daily dose ≥ 4
             weeks prior to randomization and must remain on the same dose throughout the study.
             Azathioprine, hydroxychloroquine, chloroquine, quinacrine, or methotrexate must be
             initiated ≥ 8 weeks prior to randomization.

        Exclusion Criteria:

          -  Congenital or acquired immunodeficiency including: HIV infection, agammaglobulinemias,
             T cell deficiencies or HTLV-1 infection at any time prior to the study.

          -  Lymphoproliferative disease or previous total lymphoid irradiation.

          -  Uncontrolled or poorly controlled hypertension.

          -  History of psoriasis, eczema, or relevant atopy.

          -  Exposure to excessive or chronic UV radiation (e.g., tanning beds, sunbathing,
             solarium, phototherapy) within 2 weeks prior to randomization or during the study
             period.
Clinical trial NCT00446173 (phase 2, status: withdrawn)
Conditions: leukemia
ICD codes: C95.91, C95.92, Z80.6, Z85.6, C90.11, C90.12, C91.01
Drugs: busulfan, cyclophosphamide, g-csf, gm-csf
SMILES: CS(=O)(=O)OCCCCOS(C)(=O)=O, ClCCN(CCCl)P1(=O)NCCCO1, C(N1CCCNCCNCCCNCC1)C1=CC=C(CN2CCCNCCNCCCNCC2)C=C1, COCCC1=CC=C(OCC(O)CNC(C)C)C=C1
Reason stopped: 
    terminated due to low accrual.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with Philadelphia (Ph) chromosome positive CML < age 65 and older than 21
             years.

          -  Ph positive CML that is either in: 1. late 1st chronic phase (> 2 years from
             diagnosis) 2. early chronic phase who did not achieve complete cytogenetic remission
             after one year on imatinib 3. beyond first chronic phase 4. accelerated phase 5.
             blastic phase that has responded to therapy (characterized by the presence of < 10%
             bone marrow and/or circulating blasts at consent signing) 6. chronic phase, developing
             imatinib resistance (loss of molecular remission defined as at least a 1 log increase
             in the BCR-ABL/ABL ratio, in 2 time points at least 1 month apart, or loss of
             cytogenetic remission)

          -  Patients must have a Zubrod PS < 3. Creatinine < 1.8 mg/dl

          -  Serum bilirubin </= 1.5 mg/dl

          -  Serum glutamate pyruvate transaminase (SGPT) < 3 x normal values

          -  Patients with an HLA identical sibling are eligible if they refuse allogeneic
             transplantation, or if they are ineligible for allogeneic transplantation due to age.

          -  DLCO >/= 50% of predicted

          -  Cardiac Ejection fraction >/= 40%

        Exclusion Criteria:

          -  Uncontrolled life-threatening infections or comorbid condition that could impair
             tolerance to the regimen.

          -  HIV positivity.

          -  Pregnant or lactating women.

          -  CML in blastic phase that has not responded to therapy given prior to enrollment in
             this study (characterized by the presence of more than 9% bone marrow and/or
             peripheral blood blasts at the time of consent signing)

          -  Hepatitis B or C virus infection. Hepatitis B infection defined by positive DNA test,
             positive E and / or surface antigen.

          -  CML in first molecular remission.
Clinical trial NCT00531960 (phase 2, status: completed)
Conditions: non-small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: erlotinib, bevacizumab, standard platinum-based chemotherapy
SMILES: COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Eligibility criteria:

        Inclusion Criteria:

          -  adult patients, >=18 years of age;

          -  advanced (stage IIIb and IV) non-small cell lung cancer;

          -  measurable disease;

          -  ECOG PS 0-1.

        Exclusion Criteria:

          -  prior chemotherapy or treatment with another systemic anti-cancer agent;

          -  radiotherapy within 4 weeks prior to first dose of study treatment;

          -  CNS metastases;

          -  other malignancies in past 5 years, except for adequately treated cancer in situ of
             the cervix, basal or squamous cell skin cancer.
Clinical trial NCT01065935 (phase 2, status: completed)
Conditions: respiratory syncytial virus infections
ICD codes: R09.2, A15.7, A15.8, A15.9, J98.9, R06.03, J12.1
Drugs: aln-rsv01, normal saline
SMILES: O
Eligibility criteria:

        Inclusion Criteria:

          -  Single or bilateral lung transplant recipients

          -  Confirmed RSV infection

          -  Greater than 90 days post current lung transplant

          -  Rejection free for a minimum of 30 days

        Exclusion Criteria:

          -  Known viral, bacterial, or fungal respiratory co-infection at the time of RSV
             diagnosis

          -  Bronchiolitis obliterans syndrome (BOS) Grade 3 or any BOS with FEV1 that has not been
             stable for at least 3 months

          -  Use of alemtuzumab within 9 months prior to screening, anti-thymocyte globulin (ATG)
             within 90 days of screening or prednisone or equivalent as maintenance therapy

          -  Active treatment for acute graft rejection
Clinical trial NCT00502541 (phase 2/phase 3, status: completed)
Conditions: diabetic macular edema
ICD codes: E10.311, E10.319, E11.311, E11.319, E13.311, E13.319, E10.3513
Drugs: fluocinolone acetonide
SMILES: [H][C@@]12C[C@@]3([H])[C@]4([H])C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]1(OC(C)(C)O2)C(=O)CO
Eligibility criteria:

        Inclusion Criteria:

          -  Males and nonpregnant females at least 18 years of age, with DME in the study eye

          -  Edema must involve fixation and be at least 1 disc area in size

          -  Visual acuity of ≥20 and ≤68 letters by ETDRS in the study eye

          -  The study eye must have received at least one macular laser treatment > 12 weeks prior
             to entry into the study

          -  Ability and willingness to comply with treatment and follow-up

          -  Ability to understand and sign the Informed Consent form

        Exclusion Criteria:

          -  Pregnant, lactating females

          -  Allergy to fluocinolone acetonide or any component of the delivery system

          -  Any disease or condition that would preclude study treatment or follow up

          -  Presence at screening of IOP greater or equal to 22 mm HG while on antiglaucoma
             medication(s).

          -  History of uncontrolled IOP within the last 12 months
Clinical trial NCT01516983 (phase 1/phase 2, status: completed)
Conditions: non-small cell lung cancer, brain metastases
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: icotinib
SMILES: C#CC1=CC=CC(NC2=NC=NC3=CC4=C(OCCOCCOCCO4)C=C23)=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Histological or cytological confirmation of non-small cell lung cancer (NSCLC).

          -  Diagnosis of brain metastases on a Gadolinium-enhanced MRI. More than 3 sites of
             intracranial metastases, or the longest diameter of the intracranial lesion is more
             than 3cm.

          -  Positive EGFR mutation.

        Exclusion Criteria:

          -  Previous usage of EGFR-TKI or antibody to EGFR: gefitinib, erlotinib, herceptin,
             erbitux.

          -  CSF or MRI findings consistent with metastases of spinal cord, meninges or meningeal.
Clinical trial NCT00577629 (phase 2, status: completed)
Conditions: lymphoma, b-cell
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: cyclophosphamide, etoposide, rituximab, cytarabine, doxorubicin, tositumomab
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1, ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O
Eligibility criteria:

        Inclusion Criteria:

          -  Untreated, biopsy proven B-cell non-Hodgkin's lymphoma

          -  Age >/= 18 years

          -  No other prior malignancy except for adequately treated basal cell or squamous cell
             skin cancer, in situ cervical cancer, or other cancer for which the patient has been
             disease-free for one year. The patient cannot have been exposed to chemotherapy to
             treat any of these diseases for at least 3 years prior to study entry.

          -  Meet staging studies and laboratory tests prior to induction, consolidation and
             radioimmunotherapy.

        Exclusion Criteria:

          -  Significant medical and/or psychiatric illness which may compromise planned treatment;

          -  Pregnant or lactating;

          -  HIV-infection.

          -  Patients with follicular lymphoma grade 1, 2 or 3A are not eligible for this trial.
Clinical trial NCT00143949 (phase 2, status: completed)
Conditions: type 1 diabetes
ICD codes: E10.65, E10.9, E10.21, E10.36, E10.41, E10.42, E10.44
Drugs: enalapril, losartan
SMILES: CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O, CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1
Eligibility criteria:

        Inclusion Criteria:

          -  type 1 diabetic (DM) for 2-20 yrs

          -  type 1 DM onset prior to 45; if onset was between ages 31-41, BMI <26; onset 41-45,
             positive GAD or ICA required

          -  normal or increased GFR

          -  normal BP

          -  normoalbuminuric (<20 ug/min on 2 of 3 time overnight urine collections)

        Exclusion Criteria:

          -  type 1 DM duration longer than 20 yrs

          -  hypertension (>85/135 mmHg)

          -  reduced GFR (<90 ml/min/1.73m2)

          -  microalbuminuria

          -  solitary kidney or evidence of unilateral renal disease

          -  evidence of other important kidney disease by history, ultrasound or biopsy

          -  other chronic diseases or conditions such as cystic fibrosis, serious mental illness,
             severe mental retardation, etc.

          -  pregnancy or females planning pregnancy within 2 years were excluded due to the drugs
             being used

          -  compliance (pt not taking at least 85% of two week placebo were excluded)